Irritable bowel syndrome (IBS) affects 11.2% of the global population [1], with significant impacts on patients’ quality of life despite no increased risk of mortality [2]. Among this sizeable population, there is a disproportionate number of patients <50 years [1] who would not traditionally meet criteria for endoscopy, still IBS patients accounted for up to 36% of gastroenterology consultations in one catchment area [3], with most US patients undergoing at least one outpatient procedure the year of diagnosis [4], with 28.7% of colonoscopies in those <50 performed in patients with IBS [5].
